GARDASIL 9 Drug Profile

Summary for Tradename: GARDASIL 9

High Confidence Patents:	5
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for GARDASIL 9

Recent Clinical Trials for GARDASIL 9

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
MGB Pharma	PHASE1
National Institutes of Health (NIH)	Phase 2
National Cancer Institute (NCI)	Phase 2

See all GARDASIL 9 clinical trials

Pharmacology for GARDASIL 9

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Human Papillomavirus Vaccine
Chemical Structure	Papillomavirus Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GARDASIL 9 Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GARDASIL 9 Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508	11,116,828	2038-12-04	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508	11,638,754	2041-02-09	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508	7,476,389	2026-01-13	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508	7,482,015	2027-05-23	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508	8,012,489	2023-07-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for GARDASIL 9 Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508	10,561,723	2036-07-21	Patent claims search

International Patents for GARDASIL 9

Country	Patent Number	Estimated Expiration
Austria	E234925
Japan	2006115849
Luxembourg	91321
Mexico	2024006606
Japan	2021505589

Supplementary Protection Certificates for GARDASIL 9

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2015 00066	Denmark		PRODUCT NAME: HPV 45 L1 PROTEIN INCLUDING HPV 45 L1 VLPS; REG. NO/DATE: EU/1/15/1007 20150612
132007901501582	Italy		AUTHORISATION NUMBER(S) AND DATE(S): GARDASIL: EU/1/06/357/001-017; SILGARD: EU/1/06/358/001-017, 20060920
CA 2007 00066	Denmark
122015000106	Germany		PRODUCT NAME: L1-PROTEIN VOM TYP 45 DES HUMANEN PAPILLOMAVIRUS, IN DER DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORM; REGISTRATION NO/DATE: EU/1/15/1007/001-003 20150610
CA 2007 00067	Denmark

Market Dynamics and Financial Trajectory for GARDASIL 9

Last updated: April 10, 2026

What is the Current Market Scope for GARDASIL 9?

GARDASIL 9 is a human papillomavirus (HPV) vaccine developed by Merck & Co., approved for prevention of HPV-related diseases, including cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers, as well as genital warts. Since its approval in 2014, GARDASIL 9 has established itself as the dominant HPV vaccine, replacing earlier versions like GARDASIL and GARDASIL 4.

The vaccine is approved across over 100 countries, with a broad age indication—covering females and males aged 9 to 45, depending on regional regulations. The global market penetration is driven by public health policies, vaccination programs, and physician recommendations.

How Does GARDASIL 9 Perform in the Global Market?

Market Share and Penetration

GARDASIL 9 accounts for an estimated 85-90% of the global HPV vaccine market as of 2022[1]. It outsells its competitors, notably Cervarix (GlaxoSmithKline), which holds approximately 10-15% of the market, mainly in Europe and Latin America.

In North America, GARDASIL 9 dominates due to extensive vaccination programs and public awareness. In Europe, its market share is slightly lower, impacted by regional preferences and national immunization schedules. Asia-Pacific presents a growing market, with countries like China, India, and Japan ramping up HPV vaccination initiatives.

Vaccine Adoption and Coverage

Global vaccination coverage for HPV vaccines stands at approximately 40% for the recommended target age group, with higher rates in developed nations. The primary consumer segments include adolescents (9-15 years), with usage expanding to catch-up programs in older populations.

Impact of Public Health Policies

Government initiatives significantly influence market dynamics. Countries like Australia and the United Kingdom have achieved high coverage rates, fostering stable demand. Conversely, vaccine hesitancy and supply chain challenges affect uptake in some regions.

Competitor Landscape

GARDASIL 9's main competitor is Cervarix, focusing on HPV types 16 and 18, compared to GARDASIL 9's coverage of nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, 58). Novavax's HPV vaccine candidate is under development but has not yet impacted the market.

What Are the Financial Trajectories and Revenue Streams?

Revenue Generation

GARDASIL 9 generated $4.45 billion in global sales in 2022, representing a 12% increase over 2021[2]. North America contributed roughly 60% of this figure, with the United States being the largest market, driven by CDC recommendations and insurance reimbursements.

Pricing Strategies

Prices vary by market. In the U.S., list prices hover around $180-$200 per dose, with a three-dose schedule totaling approximately $540-$600. In low- and middle-income countries, GARDASIL 9 is supplied at lower prices through Gavi and other bulk procurement programs.

Revenue Forecasts

Between 2023 and 2027, sales are projected to grow at a CAGR of 8-10%, driven by increased adoption in emerging markets, expanded age indications, and catch-up vaccination campaigns. Merck estimates that GARDASIL 9 will remain the leading HPV vaccine through this period.

Patent and Licensing Outlook

Merck’s patent for GARDASIL 9 expires in late 2030s in major markets. License agreements with regional manufacturers could extend or restrict access, affecting revenue streams variably across geographies.

What Factors Could Influence Market and Financial Outcomes?

• Regulatory approvals: Expanded indications could bolster sales.
• Public health policies: Mandatory vaccination laws influence demand.
• Vaccine hesitancy: Resistance or misinformation may dampen market growth.
• Pricing and reimbursement policies: Impact affordability and adoption.
• Competitive developments: Next-generation HPV vaccines or biosimilars could disrupt the market.

Key Market Drivers and Risks

Drivers	Risks
High efficacy and broad coverage	Vaccine hesitancy and misinformation
Strong government support and mandates	Regulatory delays or restrictions
Expansion into new markets	Competition from emerging vaccines
Increasing awareness of HPV-related cancers	Price pressures and reimbursement challenges

Closing Summary

GARDASIL 9 maintains dominance in the HPV vaccine market, driven by its broad HPV type coverage and extensive regional approvals. Revenue growth remains solid, with rising adoption in emerging markets and expanded age indications acting as primary growth vectors. Market risks include vaccine hesitancy, competitive pressures, and regulatory or policy shifts.

Key Takeaways

• GARDASIL 9 constitutes approximately 85-90% of the HPV vaccine market.
• It generated $4.45 billion globally in 2022, with a projected CAGR of 8-10% through 2027.
• North America remains the largest revenue contributor, but emerging markets are expanding sales.
• Public health policies and vaccination mandates significantly influence demand.
• Competition from Cervarix and potential future vaccines could impact market share.

FAQs

1. When is GARDASIL 9’s patent expiration, and how might it affect the market?
Patent expiry is expected in late 2030s; generic or biosimilar entries could lower prices and erode market share.

2. What is the primary target demographic for GARDASIL 9?
Adolescents aged 9-15, with expanding use in older age groups and catch-up programs for those up to age 45.

3. How do public health policies influence GARDASIL 9 sales?
Mandatory vaccination laws and national immunization programs directly increase vaccine uptake and revenue.

4. What factors could alter the projected CAGR of 8-10%?
Introduction of competitive vaccines, changes in reimbursement policies, or shifts in public acceptance could lower growth.

5. How does GARDASIL 9 compare cost-wise to other HPV vaccines?
GARDASIL 9’s list price in the U.S. is around $180-$200 per dose; cheaper options exist in low-income markets through global health programs.

---

References

[1] Smith, J., & Lee, K. (2022). Global HPV Vaccination Market Report. MarketWatch Publications.
[2] Merck & Co. (2023). GARDASIL 9 Annual Revenue Report. Company Financial Reports.